Emil Bluhme, Ewa Henckel, Carl Jorns
5 min
Pediatric patients awaiting organ transplantation face significantly higher mortality rates than adults, largely due to a severe scarcity of size-matched donor organs. While the neonatal period (the first 28 days of life) has the highest mortality rate in childhood, the use of neonatal organs remains an underutilized potential source. Historically, neonatal donation was largely abandoned in the 1990s following ethical concerns regarding anencephalic donors and the exclusion of neonates from standard neurological death criteria. However, recent re-evaluations of these guidelines and the development of donation after circulatory death (DCD) programs have renewed interest in this donor pool.
A systematic review of the literature reveals a significant theoretical pool of potential neonatal donors, though actual utilization remains sparse. Clinical reports indicate that neonatal hearts, kidneys, and livers can be successfully transplanted. For instance, heart transplants from neonatal DCD donors have shown echocardiographic outcomes comparable to those from standard brain-dead donors. Similarly, en bloc kidney transplants from neonatal donors have demonstrated that these grafts can grow significantly post-transplantation, with long-term function comparable to larger grafts.
The primary clinical hurdle in using neonatal organs is the increased risk of vascular complications. Studies on liver transplantation have reported high incidences of hepatic artery thrombosis in recipients of neonatal grafts. In kidney transplantation, similar concerns exist, though specialized surgical techniques—such as using the thoracic aorta as an inflow tract—have been employed to mitigate these risks. Additionally, neonatal hepatocytes have been used as a bridge to transplantation for metabolic disorders, showing high viability and resilience to cryopreservation, suggesting they may be a valuable therapeutic tool even when whole-organ transplantation is not immediately feasible.
Expanding the donor pool to include neonates could drastically reduce waitlist mortality for infants and small children. While the technical challenges of managing smaller, more fragile vessels are significant, the ability of these organs to grow and function effectively in recipients suggests that with refined surgical protocols and standardized donation criteria, neonatal organs could become a vital resource in pediatric medicine.
Alex: The study suggests they can, and the reason is something called biological plasticity. Young tissue has a capacity to grow and remodel itself after transplantation in a way that older tissue simply doesn't. Think of it like transplanting a young sapling rather than a mature tree — the sapling can adapt to new soil conditions, put down new roots, adjust its shape. A neonatal organ, once placed in a recipient, can grow alongside that child over time.
Sam: That's a meaningful advantage. What are the risks?
Alex: The main concern the review flags is thrombosis — that's when blood clots form inside the transplanted vessels. Because the blood vessels in neonatal organs are so narrow, there's a higher chance of a blockage forming after surgery.
Sam: Does that make the surgery too dangerous to be worthwhile?
Alex: The paper doesn't frame it that way. Surgeons use specialised techniques to connect the blood vessels — carefully managing the inflow and outflow of blood through the organ — which reduces that risk. The review notes that patient survival outcomes, while based on limited experience, are generally acceptable. The point isn't that the surgery is risk-free, but that the risk of waiting — of a child dying on a transplant list — is often higher.
Sam: So it's a comparison of risks. The surgery carries challenges, but so does doing nothing.
Alex: That's the paper's central argument. And it extends beyond the operating room. Even when a potential neonatal donor exists, the referral — the formal process of notifying the transplant team — often doesn't happen. The review notes that neonatal referral rates lag behind those for older age groups.
Sam: Why would that be?
Alex: Largely because staff in neonatal units aren't always trained to recognise or initiate the donation process. It's not that people are opposed — it's that the system isn't set up to prompt that conversation. When no one asks the question, the opportunity disappears.
Sam: So the barrier isn't just surgical. It's also about training, awareness, and having the right protocols in place.
Alex: Precisely. The paper's conclusion is that the gap between the potential of neonatal donation and its current reality isn't primarily a biological problem — it's a systems problem. Better training, clearer protocols, and more consistent referral pathways could, the authors argue, meaningfully increase the number of infants who receive a transplant in time.
Sam: It's a situation where the solution might be less about new science and more about using what we already know more consistently.
Alex: That's a fair reading. The biology is there. The surgical techniques exist. What the paper calls for is the institutional will to apply them — and to treat the neonatal donor as a legitimate, valued part of the transplant system rather than an afterthought.
Sam: For families in that situation, that distinction must matter enormously.
Alex: It does. And that's what makes this review worth paying attention to — not as a theoretical exercise, but as a practical argument for change. Thanks for listening to ResearchPod.